Use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma related disorder. The disorder may be selected from plasmacytoma (PC), plasma cell leukemia (PCL) or light chain amyloidosis (AL). The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.
